BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2718781)

  • 1. Parathyroid function in Paget's disease of bone.
    Siris ES; Clemens TP; McMahon D; Gordon A; Jacobs TP; Canfield RE
    J Bone Miner Res; 1989 Feb; 4(1):75-9. PubMed ID: 2718781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.
    Alvarez L; Guañabens N; Peris P; Monegal A; Bedini JL; Deulofeu R; Martinez de Osaba MJ; Muñoz-Gomez J; Rivera-Fillat F; Ballesta AM
    J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations in vitamin D metabolites during treatment of Paget's disease of bone with calcitonin or etidronate.
    Devlin RD; Gutteridge DH; Prince RL; Retallack RW; Worth GK
    J Bone Miner Res; 1990 Nov; 5(11):1121-6. PubMed ID: 2125401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Parathyroid function in Paget's disease of bone].
    Chapuy MC; Zucchelli P; Meunier PJ
    Rev Rhum Mal Osteoartic; 1982 Feb; 49(2):99-102. PubMed ID: 7063800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Short-term biological effects of synthetic salmon calcitonin in Paget's disease. Influence of posology].
    Chapuy MC; Meunier P; Terrier M; David L; Vignon G
    Pathol Biol (Paris); 1975 May; 23(5):349-59. PubMed ID: 172838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid, divergent changes in spinal and forearm bone density following short-term intravenous treatment of Paget's disease with pamidronate disodium.
    Price RI; Gutteridge DH; Stuckey BG; Kent GN; Retallack RW; Prince RL; Bhagat CI; Johnston CA; Nicholson GC; Stewart GO
    J Bone Miner Res; 1993 Feb; 8(2):209-17. PubMed ID: 8442439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term treatment of Paget's disease of bone with salmon calcitonin.
    Sturtridge WC; Harrison JE; Wilson DR
    Can Med Assoc J; 1977 Nov; 117(9):1031-4. PubMed ID: 562231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteocalcin and bone remodelling in Paget's disease of bone, primary hyperparathyroidism, hypercalcaemia of malignancy and involutional osteoporosis.
    Torres R; de la Piedra C; Rapado A
    Scand J Clin Lab Invest; 1989 May; 49(3):279-85. PubMed ID: 2787049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of 1 alpha-hydroxyvitamin D3 on the mineralization defect in disodium etidronate-treated Paget's disease--a double-blind randomized clinical study.
    Ralston SH; Boyce BF; Cowan RA; Fogelman I; Smith ML; Jenkins A; Boyle IT
    J Bone Miner Res; 1987 Feb; 2(1):5-12. PubMed ID: 3137773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of intravenous alendronate in Paget's disease of bone.
    O'Doherty DP; McCloskey EV; Vasikaran S; Khan S; Kanis JA
    J Bone Miner Res; 1995 Jul; 10(7):1094-100. PubMed ID: 7484285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Paget's disease of bone with porcine calcitonin: clinical and metabolic responses.
    Kanis JA; Fitzpatrick K; Strong JA
    Q J Med; 1975 Jul; 44(175):399-413. PubMed ID: 1101286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of Paget's disease of bone with ethane-1 hydroxy-1, 1 diphosphonate at low dosage (author's transl)].
    Alexandre C; Chapuy MC; Bressot C; Vignon E; Arlot M; Mathieu L; Edouard C; Johnston CC; Meunier PJ
    Nouv Presse Med; 1980 Nov; 9(45):3429-33. PubMed ID: 6777752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of 10 cases of symptomatic Paget's disease with etidronate (EHDP)].
    Jung A; Mermillod B; Schenk R; Courvoisier B; Burkhardt P; Epiney J; Fleisch
    Schweiz Med Wochenschr; 1976 Nov; 106(48):1667-73. PubMed ID: 827810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Asu(1,7)E-CT, an analog of eel calcitonin. A comparative study in man with reference to other synthetic calcitonins].
    Caniggia A; Nuti R; Vattimo A; Galli M; Turchetti V; Franci B; Martorelli T; Righi G
    Minerva Med; 1983 Apr; 74(18):993-1010. PubMed ID: 6087215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parathyroid function and vitamin D status in patients with bone metastases of prostatic origin.
    Charhon SA; Chapuy MC; Delvin EE; Meunier PJ
    Miner Electrolyte Metab; 1985; 11(2):117-22. PubMed ID: 3838794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One year's treatment of Paget's disease of bone by synthetic salmon calcitonin as a nasal spray.
    Reginster JY; Jeugmans-Huynen AM; Albert A; Denis D; Franchimont P
    J Bone Miner Res; 1988 Jun; 3(3):249-52. PubMed ID: 3213619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic balance studies in patients with Paget's disease receiving salmon calcitonin over long periods.
    Oreopoulos DG; Husdan H; Harrison J; Meema HE; McNeill KG; Murray TM; Ogilvie R; Rapoport A
    Can Med Assoc J; 1977 Apr; 116(8):851-5. PubMed ID: 856428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
    Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
    Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sarcoma arising in Paget's disease of bone: declining incidence and increasing age at presentation.
    Mangham DC; Davie MW; Grimer RJ
    Bone; 2009 Mar; 44(3):431-6. PubMed ID: 19064007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin D in Paget's disease of bone.
    Foldes J; Shamir S; Kidroni G; Menczel J
    Clin Orthop Relat Res; 1989 Jun; (243):275-9. PubMed ID: 2498022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.